In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
The US Food and Drug Administration (FDA) on Friday approved Veopoz (pozelimab-bbfg) injection, a complement inhibitor, for the treatment of adult and pediatric patients aged one year and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease. 19 August 2023
Biotechnology
Flagship Pioneering company Alltrna, which is unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, has appointed Chris Henderson, as chief scientific officer and promoted William (Will) Kiesman, to the post of chief technology officer. 19 August 2023
Pharmaceutical
Although Latin America has a broad portfolio of innovative medicines to treat orphan diseases and cancer, only 13% of patients who would benefit from these therapies have access to them. 18 August 2023
Pharmaceutical
Daewoong Pharmaceutical has already won approvals for its indigenous therapies—sodium–glucose linked transporter-2 (SGLT-2) inhibitor Envlo (enavogliflozin) and its metformin combination drug Envlomet—in South Korea. 18 August 2023
Pharmaceutical
New Jersey, USA-based Merck & Co has reported positive top-line data from a trial of its oral HIF-2α blocker Welireg (belzutifan). 18 August 2023
Generics
There has been a substantial backlash from major pharmaceutical trade associations and companies to the European Commission’s (EC) feedback initiative on the introduction of a pan-European compulsory license, which would allow for the invalidation of existing drug patents across the European Union (EU) in emergency situations. 18 August 2023
Pharmaceutical
The European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for Danish dermatology specialist LEO Pharma’s delgocitinib cream. 18 August 2023
Biotechnology
US healthcare giant Johnson & Johnson subsidiary Janssen today revealed that the European Commission (EC) has granted the approval of a Type II variation application for Tecvayli (teclistamab). 18 August 2023
Biotechnology
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) submitted by US biotech Regeneron Pharmaceuticals for its odronextamab. 18 August 2023
Biotechnology
US biotech Selecta Biosciences is to freeze investment on all pipeline assets except SEL-212, which is being developed for the treatment of chronic refractory gout. 18 August 2023
Pharmaceutical
The European Medicines Agency (EMA) has accepted for regulatory review the marketing authorization application (MAA) for avacincaptad pegol (ACP), an investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), Astellas Pharma announced today. 18 August 2023
Pharmaceutical
Forxiga (dapagliflozin) has been approved in China to reduce the risk of cardiovascular death, hospitalization for heart failure (HF), or urgent HF visits in adults with symptomatic chronic HF, UK Pharma major AstraZeneca announced this morning. 18 August 2023
Pharmaceutical
Across the globe, tense relationships between countries are on the rise. The PwC 25th Annual Global CEO Survey showed that 32% of executives cited geopolitical conflict as a top threat to growth, while 71% said it could inhibit their ability to deliver products or services. 17 August 2023
Pharmaceutical
Humanitarian organization Médecins Sans Frontières/Doctors Without Borders (MSF) revealed today that it has requested ViiV Healthcare to withdraw conditions in negotiations for a purchase agreement for an important HIV treatment. 17 August 2023
Biotechnology
UK-based Ashington Innovation has agreed to acquire in Cell Therapy Limited in a £135 million ($172 million) reverse takeover, resulting in its own shares being suspended from trading in London. 17 August 2023
Biotechnology
US drugmaker AbbVie has won approval from the European Commission (EC) for Aquipta (atogepant) for the prophylaxis of migraine in adults who have four or more migraine days per month. 17 August 2023
Biotechnology
Massachusetts, USA-based cell therapy specialist Abcuro has raised $155 million in a series B financing round co-led by Redmile Group and Bain Capital Life Sciences. 17 August 2023
Biotechnology
The US Food and Drug Administration (FDA) has told bluebird bio that an advisory committee (AdCom) meeting will not be scheduled for lovotibeglogene autotemcel (lovo-cel). 17 August 2023
Biotechnology
US clinical stage biotech Day One Biopharmaceuticals has entered into an exclusive, global license agreement and research collaboration with Sweden’s Sprint Bioscience for rights to the latter’s VRK1 program. 17 August 2023
Pharmaceutical
The USA’s Fifth Circuit Court of Appeals on Wednesday rejected an extraordinary decision blocking the US Food and Drug Administration's (FDA) decades-old approval of the widely used abortion medication mifepristone, but also upheld the decision's reinstatement of restrictions on access to the medication. 17 August 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze